Please login to the form below

Not currently logged in
Email:
Password:

Jazz Pharma

This page shows the latest Jazz Pharma news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

The latest from pharma, biotech and healthcare. Jazz Pharma gains EU approval for niche AML treatment. ... or AML with myelodysplasia-related changes,” said Daniel Swisher, president and chief operating officer at Jazz Pharmaceuticals.

Latest news

  • Jazz Pharma bags FDA approval for rare disease drug Jazz Pharma bags FDA approval for rare disease drug

    The US FDA has given the green light for Jazz Pharma's Defitelio, adding another product to the company's stable of rare disease therapies. ... Jazz acquired Defitelio as part of its $1bn purchase of Italy's Gentium in 2013.

  • Baxter buoys cancer presence with $900m Oncaspar deal Baxter buoys cancer presence with $900m Oncaspar deal

    disease therapy sector, with suggestions Shire or Jazz Pharma may be interested in the unit.

  • Shire drawn into Luxembourg tax haven exposé Shire drawn into Luxembourg tax haven exposé

    Investigations into Luxembourg's tax activities certainly stretch back several years, and this is not the first time that a pharma company has been implicated in the practice. ... Other pharma companies appearing in an ICIJ database of leaked documents -

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    Jazz expects to achieve revenues of around $870m this year, with around $570m of that total coming from Xyrem. ... Meanwhile, Jazz CEO Bruce Cozadd said the acquisition "would add a new orphan product that has potential for short- and long-term revenue

  • Jazz fibromyalgia drug not approvable

    The US Food and Drug Administration has notified Jazz Pharmaceuticals that fibromyalgia treatment JZP-6 is not approvable in its current form. ... Jazz Pharmaceuticals has been notified by the US Food and Drug Administration (FDA) that the New Drug

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    $11m. Servier. Sorrento. $821m. $28m. Jazz Pharma. Pfenex. $181m. $15m. ONO Pharma. ... Sprint BioScience/ Petre Pharma. PIP4K2a inhibitor programme. Licence. 240. Pfenex/ Jazz Pharmaceuticals.

  • Pharma deals in March 2015 Pharma deals in March 2015

    The other deal of interest is the re-emergence of EUSA Pharma with products acquired from Jazz Pharmaceuticals. ... investor, Essex Woodlands, has bought back products worth $27m and the EUSA Pharma name from Jazz for an undisclosed amount.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics